As you might know, Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) just kicked off its latest second-quarter results with some very strong numbers. Sales crushed expectations at US$14m, beating expectations by 37%. Aeglea BioTherapeutics reported a statutory loss of US$0.10 per share, which - although not amazing - was much smaller than the analysts predicted. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

See our latest analysis for Aeglea BioTherapeutics

Taking into account the latest results, the most recent consensus for Aeglea BioTherapeutics from five analysts is for revenues of US$18.9m in 2021 which, if met, would be a major 38% increase on its sales over the past 12 months. Losses are expected to hold steady at around US$1.04. Before this latest report, the consensus had been expecting revenues of US$11.3m and US$1.24 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

The consensus price target fell 5.9%, to US$13.57, suggesting that the analysts remain pessimistic on the company, despite the improved earnings and revenue outlook. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Aeglea BioTherapeutics analyst has a price target of US$20.00 per share, while the most pessimistic values it at US$9.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Aeglea BioTherapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 91% annualised revenue growth to the end of 2021 noticeably faster than its historical growth of 11% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 10% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Aeglea BioTherapeutics is expected to grow much faster than its industry.